Immune reconstitution from peripheral blood mononuclear cells inhibits lung carcinoma growth in NOD/SCID mice

Oncology Letters

Volumn 8, Issue 4, 2014, Pages 1638-1644

  Liu, Xiang ^a,b   Li, Huiling ^b,c   Liu, Jun ^b   Guan, Yubao ^b   Huang, Liyan ^b   Tang, Hailing ^b   He, Jianxing ^b  

^a THE SECOND AFFILIATED HOSPITAL OF UNIVERSITY OF SOUTH CHINA   (China)

^b GUANGZHOU MEDICAL UNIVERSITY   (China)

^c Department of Respiratory Medicine Hainan Branch of Chinese PLA General Hospital ^*  (China)

Author keywords

Am1010; Lung carcinoma; NOD SCID; Peripheral blood mononuclear cells; T lymphocytes

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; GREEN FLUORESCENT PROTEIN; IMMUNOGLOBULIN M; TRANSCRIPTION FACTOR FOXP3;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; FLOW CYTOMETRY; FLUORESCENCE IMAGING; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IMMUNE SYSTEM; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LUNG CARCINOMA; MALE; MOUSE; NONHUMAN; NORMAL HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; WESTERN BLOTTING;

EID: 84924253917     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2014.2379     Document Type: Article

References (35)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T and Thun MJ: Cancer statistics, 2008. CA Cancer J Clin 58: 71-96, 2008.
2. Nadkar A, Pungaliya C, Drake K, Zajac E, Singhal SS and Awasthi S: Therapeutic resistance in lung cancer. Expert Opin Drug Metab Toxicol 2: 753-777, 2006.
3. Levina V, Marrangoni AM, DeMarco R, Gorelik E and Lokshin AE: Drug-selected human lung cancer stem cells: cytokine network, tumorigenic and metastatic properties. PLoS One 3: e3077, 2008.
4. Wang X, Long M, Dong K, Lin F, Weng Y, Ouyang Y, Liu L, Wei J, Chen X, He T and Zhang HZ: Chemotherapy agents-induced immunoresistance in lung cancer cells could be reversed by trop-2 inhibition in vitroand in vivoby interaction with MAPK signaling pathway. Cancer Biol Ther 14: 1123-1132, 2013.
5. Li HL, Xie SM, Zhang L, Cai CJ, Wang W, Huang J, Wang DY, Wen DP, Deng QH, Zhong NS and He JX: Establishment and characterization of a new drug surviving cell line Am1010, derived directly from muscle metastases of a human lung adenocarcinoma patient with multi-drug-resistance to cisplatin, taxol, and gefitinib. Acta Pharmacol Sin 31: 601-608, 2010.
6. Prestwich RJ, Errington F, Hatfield P, Merrick AE, Ilett EJ, Selby PJ and Melcher AA: The immune system-is it relevant to cancer development, progression and treatment? Clin Oncol (R Coll Radiol) 20: 101-112, 2008.
7. Gooden MJ, de Bock GH, Leffers N, Daemen T and Nijman HW: The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer 105: 93-103, 2011.
8. Sharma P, Shen Y, Wen S, Yamada S, Jungbluth AA, Gnjatic S, Bajorin DF, Reuter VE, Herr H, Old LJ and Sato E: CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc Natl Acad Sci USA 104: 3967-3972, 2007.
9. Staibano S, Mascolo M, Tranfa F, Salvatore G, Mignogna C, Bufo P, Nugnes L, Bonavolontà G and De Rosa G: Tumor infiltrating lymphocytes in uveal melanoma: a link with clinical behavior? Int J Immunopathol Pharmacol 19: 171-179, 2006.
10. Nakamura H, Saji H, Ogata A, Hosaka M, Hagiwara M, Kawasaki N, Konaka C and Kato H: Immunologic parameters as significant prognostic factors in lung cancer. Lung Cancer 37: 161-169, 2002.
11. Pelletier MP, Edwardes MD, Michel RP, Halwani F and Morin JE: Prognostic markers in resectable non-small cell lung cancer: a multivariate analysis. Can J Surg 44: 180-188, 2001.
12. Shultz LD, Schweitzer PA, Christianson SW, Gott B, Schweitzer IB, Tennent B, McKenna S, Mobraaten L, Rajan TV, Greiner DL, et al: Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice. J Immunol 154: 180-191, 1995.
13. Smit JK, Faber H, Niemantsverdriet M, Baanstra M, Bussink J, Hollema H, van Os RP, Plukker JT and Coppes RP: Prediction of response to radiotherapy in the treatment of esophageal cancer using stem cell markers. Radiother Oncol 107: 434-441, 2013.
14. Yamauchi Y, Izumi Y, Asakura K, Kawai K, Wakui M, Ohmura M, Suematsu M and Nomori H: Lewis lung carcinoma progression is facilitated by TIG-3 fibroblast cells. Anticancer Res 33: 3791-3798, 2013.
15. van der Loo JC, Hanenberg H, Cooper RJ, Luo FY, Lazaridis EN and Williams DA: Nonobese diabetic/severe combined immunodeficiency (NOD/SCID) mouse as a model system to study the engraftment and mobilization of human peripheral blood stem cells. Blood 92: 2556-2570, 1998.
16. Kretz-Rommel A, Qin F, Dakappagari N, Cofiell R, Faas SJ and Bowdish KS: Blockade of CD200 in the presence or absence of antibody effector function: implications for anti-CD200 therapy. J Immunol 180: 699-705, 2008.
17. Xu Y, Sun J, Sheard MA, Tran HC, Wan Z, Liu WY, Asgharzadeh S, Sposto R, Wu HW and Seeger RC: Lenalidomide overcomes suppression of human natural killer cell anti-tumor functions by neuroblastoma microenvironment-associated IL-6 and TGFβ1. Cancer Immunol Immunother 62: 1637-1648, 2013.
18. Perdomo C, Campbell JD, Gerrein J, Tellez CS, Garrison CB, Walser TC, Drizik E, Si H, Gower AC, Vick J, Anderlind C, Jackson GR, Mankus C, Schembri F, O'Hara C, Gomperts BN, Dubinett SM, Hayden P, Belinsky SA, Lenburg ME and Spira A: MicroRNA 4423 is a primate-specific regulator of airway epithelial cell differentiation and lung carcinogenesis. Proc Natl Acad Sci USA 110: 18946-18951, 2013.
19. Maes E, Landuyt B, Mertens I and Schoofs L: Interindividual variation in the proteome of human peripheral blood mononuclear cells. PLoS One 8: e61933, 2013.
20. Dai YQ, Jin DZ, Zhu XZ and Lei DL: Triptolide inhibits COX-2 expression via NF-kappa B pathway in astrocytes. Neurosci Res 55: 154-160, 2006.
21. D'Antonio C, Passaro A, Gori B, Del Signore E, Migliorino MR, Ricciardi S, Fulvi A and de Marinis F: Bone and brain metastasis in lung cancer: recent advances in therapeutic strategies. Ther Adv Med Oncol 6: 101-114, 2014.
22. Wang C, Xiao Q, Li YW, Zhao C, Jia N, Li RL, Cao SS, Cui J, Wang L, Wu Y and Wen AD: Regulatory mechanisms of annexin-induced chemotherapy resistance in cisplatin resistant lung adenocarcinoma. Asian Pac J Cancer Prev 15: 3191-3194, 2014.
23. Greiner DL, Shultz LD, Yates J, Appel MC, Perdrizet G, Hesselton RM, Schweitzer I, Beamer WG, Shultz KL, Pelsue SC, et al: Improved engraftment of human spleen cells in NOD/LtSz-scid/scid mice as compared with C. B-17-scid/scid mice. Am J Pathol 146: 888-902, 1995.
24. Hesselton RM, Greiner DL, Mordes JP, Rajan TV, Sullivan JL and Shultz LD: High levels of human peripheral blood mononuclear cell engraftment and enhanced susceptibility to human immunodeficiency virus type 1 infection in NOD/LtSz-scid/scid mice. J Infect Dis 172: 974-982, 1995.
25. Lee YS, Kim TS and Kim DK: T lymphocytes derived from human cord blood provide effective antitumor immunotherapy against a human tumor. BMC Cancer 11: 225, 2011.
26. Liu H, Zhang T, Ye J, Li H, Huang J, Li X, Wu B, Huang X and Hou J: Tumor-infiltrating lymphocytes predict response to chemotherapy in patients with advance non-small cell lung cancer. Cancer Immunol Immunother 61: 1849-1856, 2012.
27. Morris M, Platell C and Iacopetta B: Tumor-infiltrating lymphocytes and perforation in colon cancer predict positive response to 5-fluorouracil chemotherapy. Clin Cancer Res 14: 1413-1417, 2008.
28. Lee WS, Kang M, Baek JH, Lee JI and Ha SY: Clinical impact of tumor-infiltrating lymphocytes for survival in curatively resected stage IV colon cancer with isolated liver or lung metastasis. Ann Surg Oncol 20: 697-702, 2013.
29. Batchelder CA, Duru N, Lee CI, Baker CA, Swainson L, Mccune JM and Tarantal AF: Myeloid-lymphoid ontogeny in the rhesus monkey (Macaca mulatta). Anat Rec (Hoboken): May 28, 2014 (Epub ahead of print).
30. Fearon ER, Pardoll DM, Itaya T, Golumbek P, Levitsky HI, Simons JW, Karasuyama H, Vogelstein B and Frost P: Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 60: 397-403, 1990.
31. Rosenberg SA: A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 10: 281-287, 1999.
32. Al-Shibli KI, Donnem T, Al-Saad S, Persson M, Bremnes RM and Busund LT: Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer. Clin Cancer Res 14: 5220-5227, 2008.
33. Fridman WH, Pagès F, Sautès-Fridman C and Galon J: The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 12: 298-306, 2012.
34. Donnem T, Al-Shibli K, Andersen S, Al-Saad S, Busund LT and Bremnes RM: Combination of low vascular endothelial growth factor A (VEGF-A)/VEGF receptor 2 expression and high lymphocyte infiltration is a strong and independent favorable prognostic factor in patients with nonsmall cell lung cancer. Cancer 116: 4318-4325, 2010.
35. Ganesan AP, Johansson M, Ruffell B, Beltran A, Lau J, Jablons DM and Coussens LM: Tumor-infiltrating regulatory T cells inhibit endogenous cytotoxic T cell responses to lung adenocarcinoma. J Immunol 191: 2009-2017, 2013.